Therapeutic Solutions International, Inc. (TSOI)
| Previous close | 0.0007 |
| Open | 0.0007 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0005 - 0.0007 |
| 52-week range | 0.0004 - 0.0033 |
| Volume | |
| Avg. volume | 25,487,114 |
| Market cap | 2.538M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings date | 16 May 2024 - 20 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireTherapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients
ELK CITY, Idaho, March 04, 2024--Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19. NK cells are the first line of defense against viruses and cancers1.
Business WireTherapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell Product
ELK CITY, Idaho, February 29, 2024--Therapeutic Solutions International, Inc. (TSOI), announced today results of ongoing experiments demonstrating that the healing effects of JadiCells appear to be mediated by a biological mechanism involving interplay between two types of immunological cells found in the body.
Business WireTherapeutic Solutions International Files Patent on "Facilitating Effects" of JadiCells on Gene Therapy Mediated Cell Differentiation
ELK CITY, Idaho, February 26, 2024--Therapeutic Solutions International, Inc. (TSOI), announced today data demonstrating that JadiCell administration is capable of increasing gene therapy mediated production of therapeutic cells in vivo.
